Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis

References

• Di LerniaVFicarelliELallasARicciCFamilial aggregation of moderate to severe plaque psoriasisClin Exp Dermatol20143980180525156221
   PubMed Web of Science ®Google Scholar
• BoehnckeWHEtiology and pathogenesis of psoriasisRheum Dis Clin North Am20154166567526476225
   PubMed Web of Science ®Google Scholar
• Di LerniaVFicarelliECurrent therapeutic approaches of psoriasis are affected by age at disease onsetJ Dermatolog Treat201425151723210896
   PubMed Web of Science ®Google Scholar
• HenselerTChristophersEPsoriasis of early and late onset: characterization of two types of psoriasis vulgarisJ Am Acad Dermatol1985134504564056119
   PubMed Web of Science ®Google Scholar
• GladmanDDAntoniCMeasePCleggDONashPPsoriatic arthritis: epidemiology, clinical features, course, and outcomeAnn Rheum Dis200564Suppl 2ii14ii1715708927
   PubMed Web of Science ®Google Scholar
• GelfandJMNeimannALShinDBWangXMargolisDJTroxelABRisk of myocardial infarction in patients with psoriasisJAMA2006112961735174117032986
   PubMedGoogle Scholar
• GisondiPDalle VedoveCGirolomoniGPatients with psoriasis have a higher prevalence of parental cardiovascular diseaseDermatology201122233033521701147
   PubMed Web of Science ®Google Scholar
• GisondiPTargherGBardazziFPharmacological treatment of moderate-severe psoriasis in patients with cardio-metabolic comorbiditiesG Ital Dermatol Venereol2014149Suppl 2711
   Google Scholar
• GisondiPTessariGContiAPrevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control studyBr J Dermatol2007157687317553036
   PubMed Web of Science ®Google Scholar
• RyanCKirbyBPsoriasis is a systemic disease with multiple cardiovascular and metabolic comorbiditiesDermatol Clin201533415525412782
   PubMed Web of Science ®Google Scholar
• MrowietzUKragballeKReichKDefinition of treatment goals for moderate to severe psoriasis: a European consensusArch Dermatol Res201130311020857129
   PubMed Web of Science ®Google Scholar
• GirolomoniGAltomareGAyalaFDifferential management of mild-to-severe psoriasis with biologic drugs: an Italian Delphi consensus expert panelJ Dermatolog Treat20152612813324708158
   PubMed Web of Science ®Google Scholar
• WegerWCurrent status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agentsBr J Pharmacol201016081082020590580
   PubMed Web of Science ®Google Scholar
• DuboisDSPouliotRPromising new treatments for psoriasisScientific World J20132013980419
   Google Scholar
• GniadeckiRKragballeKDamTNSkovLComparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgarisBr J Dermatol20111641091109621219290
   PubMed Web of Science ®Google Scholar
• YeungHWanJVan VoorheesASPatient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasisJ Am Acad Dermatol201368647222846688
   PubMed Web of Science ®Google Scholar
• Di LerniaVRicciCLallasAFicarelliEClinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective studyJ Dermatolog Treat201425737423621374
   PubMed Web of Science ®Google Scholar
• Di LerniaVTasinLPellicanoRImpact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasisJ Dermatolog Treat20122340440921781016
   PubMed Web of Science ®Google Scholar
• De SimoneCAmerioPAmorusoGImmunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?Expert Opin Biol Ther2013131673168224107126
   PubMed Web of Science ®Google Scholar
• ArmstrongAWRobertsonADWuJSchuppCLebwohlMGUndertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003–2011JAMA Dermatol20131491180118523945732
   PubMed Web of Science ®Google Scholar
• MansouriYGoldenbergGNew systemic therapies for psoriasisCutis20159515516025844781
   PubMed Web of Science ®Google Scholar
• PattersonHNibbsRMcInnesISiebertSProtein kinase inhibitors in the treatment of inflammatory and autoimmune diseasesClin Exp Immunol201417611024313320
   PubMed Web of Science ®Google Scholar
• MurrayPJThe JAK-STAT signaling pathway: input and output integrationJ Immunol20071782623262917312100
   PubMed Web of Science ®Google Scholar
• VelazquezLFellousMStarkGRPellegriniSA protein tyrosine kinase in the interferon α/β signaling pathwayCell1992703133221386289
   PubMed Web of Science ®Google Scholar
• MullerMBriscoeJLaxtonCThe protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transductionNature19933661291358232552
   PubMed Web of Science ®Google Scholar
• DarnellJEJrKerrIMStarkGRJak–STAT pathways and transcriptional activation in response to IFNs and other extracellular signalling proteinsScience1994264141514218197455
   PubMed Web of Science ®Google Scholar
• O’SheaJJGadinaMSchreiberRDCytokine signaling in 2002: new surprises in the Jak/Stat pathwayCell2002109121131
   PubMed Web of Science ®Google Scholar
• LeonardWJO’SheaJJJaks and STATs: biological implicationsAnnu Rev Immunol1998162933229597132
   PubMed Web of Science ®Google Scholar
• LindstromTMRobinsonWHA multitude of kinases – which are the best targets in treating rheumatoid arthritis?Rheum Dis Clin North Am20103636738320510239
   PubMed Web of Science ®Google Scholar
• GhoreschiKGadinaMJAKpot! New small molecules in autoimmune and inflammatoryExp Dermatol20142371124131352
   PubMed Web of Science ®Google Scholar
• BorieDCO’SheaJJChangelianPSJAK3 inhibition, a viable new modality of immunosuppression for solid organ transplantsTrends Mol Med20041053254115519279
   PubMed Web of Science ®Google Scholar
• MacchiPVillaAGilianiSMutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)Nature199537765687659163
   PubMed Web of Science ®Google Scholar
• ChiricozziAFaleriSSaracenoRTofacitinib for the treatment of moderate-to-severe psoriasisExpert Rev Clin Immunol20151144345525666451
   PubMed Web of Science ®Google Scholar
• KyttarisVCKinase inhibitors: a new class of antirheumatic drugsDrug Des Devel Ther20126245250
   PubMed Web of Science ®Google Scholar
• ChangBYZhaoFHeXJAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J miceJ Immunol20091832183219219596999
   PubMed Web of Science ®Google Scholar
• GhoreschiKJessonMILiXModulation of innate and adaptive immune responses by tofacitinib (CP-690, 550)J Immunol20111864234424321383241
   PubMed Web of Science ®Google Scholar
• FridmanJSScherlePACollinsRSelective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050J Immunol20101845298530720363976
   PubMed Web of Science ®Google Scholar
• BoyMGWangCWilkinsonBEDouble-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasisJ Invest Dermatol20091292299230219225543
   PubMed Web of Science ®Google Scholar
• KuboSYamaokaKKondoMThe JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cellsAnn Rheum Dis2014732192219824013646
   PubMed Web of Science ®Google Scholar
• GhoreschiKLaurenceAO’SheaJJJanus kinases in immune cell signallingImmunol Rev200922827328719290934
   PubMed Web of Science ®Google Scholar
• HsuLArmstrongAWJAK inhibitors: treatment efficacy and safety profile in patients with psoriasisJ Immunol Res2014201428361724883332
   PubMed Web of Science ®Google Scholar
• PesuMLaurenceAKishoreNZwillichSHChanGO’SheaJJTherapeutic targeting of Janus kinasesImmunol Rev200822313214218613833
   PubMed Web of Science ®Google Scholar
• PappKAMenterMAAbeMTofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsBr J Dermatol201517394996126149717
   PubMed Web of Science ®Google Scholar
• BachelezHvan de KerkhofPCStrohalRTofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trialLancet201538655256126051365
   PubMed Web of Science ®Google Scholar
• BissonnetteRIversenLSofenHTofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trialBr J Dermatol20151721395140625418186
   PubMed Web of Science ®Google Scholar
• MeyerDMJessonMILiXAnti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritisJ Inflamm (Lond)201074120701804
   PubMed Web of Science ®Google Scholar
• WinthropKLParkSHGulATuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritisAnn Rheum Dis Epub201582810.1136/annrheumdis-2015-207319
   Web of Science ®Google Scholar
• WollenhauptJSilverfieldJLeeEBSafety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long term extension studiesJ Rheumatol20144183785224692527
   PubMed Web of Science ®Google Scholar
• StrandVAhadiehSFrenchJSystematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trialsArthritis Res Ther20151736226669566
   PubMed Web of Science ®Google Scholar
• XELJANZ® (tofacitinib) tablets [prescribing information]New YorkPfizer Labs2012 Available from:http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203214s000lbl.pdfAccessed 19 January, 2016
   Google Scholar
• GuptaPAlveyCWangRLack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro dataBr J Clin Pharmacol20127410911522233204
   PubMed Web of Science ®Google Scholar
• PortsWCKhanSLanSA randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasisBr J Dermatol201316913714523387374
   PubMed Web of Science ®Google Scholar
• PortsWCFeldmanSRGuptaPRandomized pilot clinical trial of tofacitinib solution for plaque psoriasis: challenges of the intra-subject study designJ Drugs Dermatol20151477778426267721
   PubMed Web of Science ®Google Scholar
• LeeEBFleischmannRHallSTofacitinib versus methotrexate in rheumatoid arthritisN Engl J Med20143702377238624941177
   PubMed Web of Science ®Google Scholar
• van VollenhovenRFFleischmannRCohenSTofacitinib or adalimumab versus placebo in rheumatoid arthritisN Engl J Med201236750851922873531
   PubMed Web of Science ®Google Scholar
• VivarNVan VollenhovenRFAdvances in the treatment of rheumatoid arthritisF1000Prime Rep201463124860653
   PubMedGoogle Scholar
• BrittanyGCraiglowKingBAKilling two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasisJ Invest Dermatol20141342988299024940651
   PubMed Web of Science ®Google Scholar
• CraiglowBGKingBATofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapyJAMA Dermatol20151511110111226107994
   PubMed Web of Science ®Google Scholar
• XingLDaiZJabbariAAlopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibitionNat Med2014201043104925129481
   PubMed Web of Science ®Google Scholar
• HarelSHigginsCACeriseJEPharmacologic inhibition of JAK-STAT signaling promotes hair growthSci Adv2015231e150097326601320
   PubMedGoogle Scholar
• RashighiMAgarwalPRichmondJMCXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligoSci Transl Med20146223
   Web of Science ®Google Scholar
• LevyLLUrbanJKingBATreatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrateJ Am Acad Dermatol20157339539926194706
   PubMed Web of Science ®Google Scholar